168 related articles for article (PubMed ID: 33145271)
1. Tumor mutation burden and
Zhang X; Li J; Yang Q; Wang Y; Li X; Liu Y; Shan B
Ann Transl Med; 2020 Sep; 8(17):1052. PubMed ID: 33145271
[TBL] [Abstract][Full Text] [Related]
2. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
[TBL] [Abstract][Full Text] [Related]
3. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
4. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
Zhu M; Liang C; Zhang F; Zhu L; Chen D
Front Oncol; 2021; 11():690336. PubMed ID: 34745934
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of the PTPN13 expression and its clinical implication in breast cancer.
Li JP; Zhang XM; Liu BC; Ren SG; Zhao XH; Liu YJ
Neoplasma; 2023 Apr; 70(2):188-198. PubMed ID: 36812232
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of the
Bai H; Yu J; Jia S; Liu X; Liang X; Li H
Cancer Manag Res; 2021; 13():3303-3316. PubMed ID: 33889023
[TBL] [Abstract][Full Text] [Related]
7. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].
Wang X; Yue J; Kang YK; Gao SL; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):787-795. PubMed ID: 37805443
[No Abstract] [Full Text] [Related]
8. Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications.
Tierno D; Grassi G; Scomersi S; Bortul M; Generali D; Zanconati F; Scaggiante B
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298642
[TBL] [Abstract][Full Text] [Related]
9. A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
Huang L; Lang GT; Liu Q; Shi JX; Shao ZM; Cao AY
Ann Transl Med; 2021 Feb; 9(4):301. PubMed ID: 33708928
[TBL] [Abstract][Full Text] [Related]
10. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
11. Genomic Profiling Comparison of Germline
Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q
Front Oncol; 2020; 10():583314. PubMed ID: 33194720
[No Abstract] [Full Text] [Related]
12. Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
Jin HY; He W; Liu Q; Wang XF; Liu YF; Wei ZX
Neoplasma; 2016; 63(4):607-16. PubMed ID: 27268925
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
14. The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients.
Li P; Sun T; Yuan Q; Pan G; Zhang J; Sun D
Onco Targets Ther; 2016; 9():5751-5759. PubMed ID: 27703373
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Fasching PA; Loibl S; Hu C; Hart SN; Shimelis H; Moore R; Schem C; Tesch H; Untch M; Hilfrich J; Rezai M; Gerber B; Costa SD; Blohmer JU; Fehm T; Huober J; Liedtke C; Weinshilboum RM; Wang L; Ingle JN; Müller V; Nekljudova V; Weber KE; Rack B; Rübner M; von Minckwitz G; Couch FJ
J Clin Oncol; 2018 Aug; 36(22):2281-2287. PubMed ID: 29791287
[TBL] [Abstract][Full Text] [Related]
16. Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
Li M; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Gene; 2016 Jun; 584(1):26-30. PubMed ID: 26956035
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.
Li Z; Han Y; Wang J; Xu B
J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836424
[TBL] [Abstract][Full Text] [Related]
18. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
19. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
